Apomorphine subcutaneous - Britannia Pharmaceuticals

Drug Profile

Apomorphine subcutaneous - Britannia Pharmaceuticals

Alternative Names: APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; MOVAPO®

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; Kyowa Hakko Kirin; STADA Arzneimittel; US WorldMeds
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 10 Aug 2017 Apomorphine is still in phase III trials for Parkinson's disease in USA, Austria, Denmark, France, Germany, Netherlands and Spain (SC,infusion) (NCT02339064) (EudraCT2013-000980-10)
  • 25 Apr 2017 Efficacy data from the phase III TOLEDO trial in Parkinson's Disease released by Britannia Pharmaceuticals
  • 24 Mar 2015 Launched for Parkinson's disease in China, Bulgaria, France, Estonia, Italy, Latvia, Norway, Slovenia and Switzerland (SC) before March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top